MedTrace Logo

Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection

NCT04019717 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2020-05-04

No results posted yet for this study

Summary

The study will assess the safety and efficacy of AT-527 in combination with daclatasvir after 8 or 12 weeks of treatment.

Conditions

  • Hepatitis C
  • Hepatitis C, Chronic
  • Chronic Hepatitis C
  • Hepatitis C Virus Infection
  • HCV Infection

Interventions

DRUG

AT-527

Nucleotide prodrug inhibitor of HCV nonstructural protein 5B (NS5B) polymerase

DRUG

Daclatasvir

Inhibitor of HCV nonstructural protein 5A (NS5A)

Sponsors & Collaborators

  • Atea Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Xiao-Jian Zhou, PhD · Atea Pharmaceuticals, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-20
Primary Completion
2020-01-29
Completion
2020-03-23

Countries

  • Belgium
  • Mauritius
  • Moldova

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04019717 on ClinicalTrials.gov